STI-5656

Sorrento Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	STI-5656
Also known as	abivertinib maleate, avitinib, AC0010, abivertinib
Sponsor	Sorrento Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer (PHASE2)
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 (PHASE2)
Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

STI-5656 CI brief — competitive landscape report
STI-5656 updates RSS · CI watch RSS
Sorrento Therapeutics, Inc. portfolio CI